| Research Support |
National Institutes of Health - NINDS-R01 NS 24224
"Stroke Prevention in Atrial Fibrillation II (SPAF II) Trial” (9/90 through 8/93)
Principal Investigator (National): Robert G. Hart, MD
National Institutes of Health - NINDS-R01 NS24224
“Stroke Prevention in Atrial Fibrillation III (SPAF III) Trial” (9/93 through 8/97)
Principal Investigator (National): Robert G. Hart, MD
National Institutes of Health (NHLBI)
“Transesophageal Echocardiography in Atrial Fibrillation” (4/94 through 3/98)
Principal Investigator (National): Jonathan Halperin, MD
Booth Laboratories, Inc.
“Survival With ORal D- Trial” (7/93 through 7/95)
Gensia Laboratories, Inc.“Arbutamine in Coronary Artery Disease” (1/94 to 6/95)
Molecular Biosystems, Inc.
“A Comparative Study for the Clinical Evaluation of FS 069 in Assessing Myocardial Contrast” (1/94 through 7/95)
Astra/Merck Group, Inc.
"Hypertension Optimal Treatment Study” (7/93 to 10/97)
Astra/Merck Group, Inc.
“Echo/Doppler Assessment of LV Hypertrophy Regression: A substudy of the HOT Trial” (7/93 through 10/97)
Duke Clinical Research Institute
“Sibrafiban, an oral platelet glycoprotein Ilb/IIIa receptor antagonist, for prevention of vascular events after an ACS” (2nd Symphony Trial) (1/99 through 12/99)
Egyptian Embassy, Department of Scientific Affairs
“Assessment of CAD by Stress Transesophageal Echocardiography” (Thesis) (10/93 through 9/95)
Dr. Magdy F. Ismaeil defended his thesis at Suez Canal University, Egypt.
DuPont Pharmaceuticals Company
“An Open-Label, Randomized, Phase IIIB, Multi-Center Trial to Compare the Ability of DMP 115 Contrast-Enhanced Exercise Echo” (3/00 to 3/01)
Searle Laboratories, Inc.
“Controlled ONset Verapamil INvestigation of Cardiac Endpoints (CONVINCE) Trial” (4/97 though 1/2001)
Merck, Inc.
“Losartan Intervention For End-points (LIFE) in Hypertension Study” (1/96 through 9/2001)
National Institutes of Health (NO1-HC-55139)
“Atrial Fibrillation Follow-up Investigation of Rhythm
Management (AFFIRM) Trial” (4/96 through 10/2001)
Egyptian Embassy, Department of Scientific Affairs
“Assessment of Myocardial Perfusion Using Intravenous Contrast Echocardiography” (Thesis) (1/99 through 1/02)
Trainee: Mohamed A. Oraby, MD
AstraZeneca, Inc.
“Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin in the Prevention of Stroke and Systemic Events in Patients with Atrial Fibrillation (SPORTIF V) Trial”.
AstraZeneca, Inc.
“Efficacy and Safety of H 376/95 & Aspirin in Patients with a Recent Acute Coronary Syndrome with Elevated Biochemical Markers. A Multicenter, double-blind, controlled, dose-guiding study - ESTEEM” (10/01 - 2/03)
National Institutes of Health (NHLBI)
“Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial” (6/97 through 12/2003)
Department of Defense
“Disease Management versus Disease Management plus Technology in Patients with CHF” (1/00 to 12/03)
Principal Investigator: Gregory L. Freeman, MD.
POINT Biomedical Corporation
“A Phase 3 Clinical Trial to Assess Perfusion and Obstruction Identified by Non-invasive Technology using PB127 Ultrasound Contrast Agent in Patients with Suspected Obstructive Coronary Artery Disease”
Novartis
“A Multicenter, Randomized, Placebo-controlled, Double-blind study to evaluate the effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients with Hypertension and Diastolic Dysfunction” 04/04 to 12/06.
The Medicines Company
“A randomized comparison of Angiomax versus heparin in patients undergoing early invasive management for ACS without ST elevation” ACUITY trial 7/04-12/06
Berlex
“FGF in patients with advanced coronary artery disease”
Role: Participant of a multicenter trial.
Acusphere, Inc
“A Phase 3, International, Multicenter, Echo Imaging and Safety of AI-700 in Patients with Ischemic Heart Disease Undergoing Coronary Angiography” 04/04 to 04/06.
Role: Stress echo with AI-700, SPECT, and coronary angio in patients with suspected CAD to define accuracy.
|